Il2 - interleukin 2 Gene
Also Known as Il-2
Species: Mus musculus
Gene Type: protein coding
Gene ID: 16183
About Il2
Chromosome 3: 37,174,672-37,180,108 reverse strand.GRCm39:CM000996.3
This gene has 1 transcript (splice variant), 89 orthologues and is associated with 95 phenotypes. Low expression observed in reference dataset.
Summary
Enables cytokine activity and interleukin-2 receptor binding activity. Involved in negative regulation of T-helper 17 cell differentiation. Acts upstream of or within several processes, including extrinsic apoptotic signaling pathway in absence of ligand; positive regulation of macromolecule metabolic process; and regulation of lymphocyte activation. Located in extracellular space. Is expressed in liver; omental bursa; thymus; and thymus primordium. Used to study Sjogren's syndrome and inflammatory bowel disease. Human ortholog(s) of this gene implicated in several diseases, including Takayasu's arteritis; auditory system disease (multiple); autoimmune disease (multiple); carcinoma (multiple); and neurodegenerative disease (multiple). Orthologous to human IL2 (interleukin 2). [provided by Alliance of Genome Resources, Apr 2022]
Il2 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_008366.3 | NP_032392.1 | interleukin-2 precursor |
| Molecular Function GO Annotation | Evidence | References | Source |
|---|---|---|---|
| enables cytokine activity |
IDA
IDA: Inferred from direct assay
|
1588041 | MGI |
| enables cytokine activity |
IMP
IMP: Inferred from mutant phenotype
|
12874832 | MGI |
| enables interleukin-2 receptor binding |
IDA
IDA: Inferred from direct assay
|
1588041 | MGI |
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| located in extracellular space |
IDA
IDA: Inferred from direct assay
|
1830926 | MGI |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
Il2 Protein Structure
IL2
IL2: smart00189 (0 - 167)
- 0
- 100
- 169 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
interleukin-2 |
|
Recombinant Il2 Proteins
| Cat. No. | Product Name | Accession | Purity |
|---|---|---|---|
| HY-P7077 | IL-2 Protein, Mouse | P04351 (A21-Q169) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P78151 | IL-2 Protein, Mouse (Biotinylated, HEK293, His-Avi) | P04351 (A21-Q169) | ≥ 95%, as determined by Bis-Tris PAGE. |
| HY-P78312 | IL-2 Protein, Mouse (HEK293, His-Avi) | P04351 (A21-Q169) | ≥ 95%, as determined by reducing SDS-PAGE or Bis-Tris PAGE. |
| HY-P70646AF | Animal-Free IL-2 Protein, Mouse (His) | P04351 (A21-Q169) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(12)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-13756 | Tacrolimus | 99.93% | Unkown | |
| HY-A0003 | Lenalidomide | Inducer | 99.94% | Yes |
| HY-100754 | Ritlecitinib | Inhibitor | 99.80% | Yes |
| HY-B1046 | Clofazimine | 99.79% | Unkown | |
| HY-13756A | Tacrolimus monohydrate | 99.93% | Yes | |
| HY-A0003B | Lenalidomide hemihydrate | Inducer | 99.98% | Yes |
| HY-B0072 | Tropisetron | 99.93% | Unkown | |
| HY-B0199A | Mycophenolate mofetil hydrochloride | Inhibitor | 99.17% | Yes |
| HY-100754C | Ritlecitinib tosylate | Inhibitor | 99.65% | Yes |
| HY-B0199R | Mycophenolate Mofetil (Standard) | Inhibitor | 99.86% | Unkown |
| HY-A0003A | Lenalidomide hydrochloride | / | Unkown | |
| HY-100754A | Ritlecitinib malonate | Inhibitor | / | Unkown |
Inhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-108738 | Daclizumab | ≥99.0% | Unkown |
Clinical Phase
Bioactive Molecules
(12)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-Y0344D | Sodium chloride, for cell culture | Activator | 99.9% | Phase 4 |
| HY-126404 | Casein hydrolysate | / | Phase 4 | |
| HY-113271 | 5-Androstenetriol | Activator | / | Phase 4 |
| HY-13743 | Roquinimex | Inhibitor | 99.69% | Phase 3 |
| HY-13644 | Gusperimus | / | Phase 3 | |
| HY-13743R | Roquinimex (Standard) | Inhibitor | / | Phase 3 |
| HY-106755 | Tucaresol | Inhibitor | 97.50% | Phase 2 |
| HY-111167 | AN-2898 | Inhibitor | / | Phase 2 |
| HY-137131 | DC-Chol hydrochloride | 99.95% | Phase 1 | |
| HY-132304 | CC-90005 | Inhibitor | 99.11% | Phase 1 |
| HY-P1997 | Ferrichrome Iron-free | 98.5% | Phase 1 | |
| HY-173006 | AZ3246 | 98.92% | Phase 1 |
Inhibitory Antibodies
(25)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P991028 | Surovatamig | Inhibitor | 99.89% | Phase 3 |
| HY-P991740 | IBI-363 | Inhibitor | 99.60% | Phase 3 |
| HY-P991214 | Tucotuzumab celmoleukin | 98.797% | Phase 3 | |
| HY-P99499 | Cetrelimab | ≥99.0% | Phase 3 | |
| HY-P99664 | Inolimomab | Inhibitor | 98.78% | Phase 3 |
| HY-P99410 | Ordesekimab | Inhibitor | 99.08% | Phase 2 |
| HY-P99159 | Ivuxolimab | Activator | ≥99.0% | Phase 2 |
| HY-P99752 | Nemvaleukin alfa | 99.50% | Phase 2 | |
| HY-P99328 | Tucotuzumab | 99% | Phase 2 | |
| HY-P99728 | Melredableukin alfa | 96.22% | Phase 2 | |
| HY-P99902 | Simlukafusp alfa | Inhibitor | 99.90% | Phase 2 |
| HY-P991000 | Imneskibart | Inhibitor | 99.0% | Phase 2 |
| HY-P990716 | Sabestomig | Inhibitor | 98.33% | Phase 2 |
| HY-P99479 | Bifikafusp alfa | Inhibitor | 96% | Phase 2 |
| HY-P990992 | Efzilonkofusp alfa | / | Phase 2 | |
| HY-P991566 | KD6001 | Inhibitor | / | Phase 2 |
| HY-P991960 | JS007 | / | Phase 2 | |
| HY-P991201 | REGN-7257 | Inhibitor | 95.34% | Phase 1 |
| HY-P990086 | Vopikitug | Inhibitor | 98.32% | Phase 1 |
| HY-P99498 | Cergutuzumab amunaleukin | Inhibitor | 99.5% | Phase 1 |
| HY-P991279 | Mik-Beta-1 | Inhibitor | ≥99.0% | Phase 1 |
| HY-P991353 | Sym-021 | Antagonist | / | Phase 1 |
| HY-P991393 | ASP8374 | / | Phase 1 | |
| HY-P991634 | IBI-325 | Inhibitor | / | Phase 1 |
| HY-P991678 | Efpixileukin alfa | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(180)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-126370A | Geranylgeranyl pyrophosphate triammonium | ≥95.0% | Unkown | |
| HY-131140 | BD750 | Inhibitor | 99.02% | Unkown |
| HY-110117 | BIRT 377 | Inhibitor | 99.82% | Unkown |
| HY-N6607 | Tryptanthrin | 99.89% | Unkown | |
| HY-133987 | AP-1/NF-κB activation inhibitor 1 | Inhibitor | 98.08% | Unkown |
| HY-136339 | Cbl-b-IN-1 | Inhibitor | 99.66% | Unkown |
| HY-18303 | AMG-47a | Inhibitor | 99.19% | Unkown |
| HY-110177 | SP-100030 | Inhibitor | 99.57% | Unkown |
| HY-113494 | Sitostanol | Activator | 99.0% | Unkown |
| HY-155978A | RDN2150 TFA | Inhibitor | 99.80% | Unkown |
| HY-N6939 | Pseudolaric Acid B | 99.47% | Unkown | |
| HY-100712 | DPO-1 | Inhibitor | 98.39% | Unkown |
| HY-113618B | RO2959 monohydrochloride | Inhibitor | 98.03% | Unkown |
| HY-138568 | HPK1-IN-3 | Inhibitor | 98.61% | Unkown |
| HY-159647 | PLX-4545 | 96.76% | Unkown | |
| HY-N0534 | Vitexin-2"-O-rhamnoside | 99.78% | Unkown | |
| HY-171034 | PQA-18 | Inhibitor | 99.62% | Unkown |
| HY-13756S | Tacrolimus-13C,d2 | 98.36% | Unkown | |
| HY-N4087 | Platycodin D2 | Inducer | 99.84% | Unkown |
| HY-126328 | PKC-theta inhibitor 1 | Inhibitor | 99.45% | Unkown |
| HY-N0594 | Deacetylasperulosidic Acid | 99.44% | Unkown | |
| HY-Y0344J | Sodium chloride, for molecular biology | 99.97% | Unkown | |
| HY-121638A | (5Z,2E)-CU-3 | 95.03% | Unkown | |
| HY-162943 | P60-L3-VHL | 99.84% | Unkown | |
| HY-W722277A | LCC-12 formate | Inhibitor | 99.90% | Unkown |
| HY-Y0344I | Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al | 99.99% | Unkown | |
| HY-N0600 | Ginsenoside F3 | 99.84% | Unkown | |
| HY-P3143 | BMSpep-57 | Inhibitor | 99.87% | Unkown |
| HY-B0199S | Mycophenolate Mofetil-d4 | Inhibitor | 99.80% | Unkown |
| HY-134820 | MLT-943 | Inhibitor | 99.71% | Unkown |
| HY-139617 | Sec61-IN-3 | Inhibitor | 99.22% | Unkown |
| HY-P1453A | CMD178 TFA | Inhibitor | 99.71% | Unkown |
| HY-119424 | SP4206 | Inhibitor | 96.97% | Unkown |
| HY-139616 | Sec61-IN-2 | Inhibitor | 99.51% | Unkown |
| HY-N2571 | Corydine | 99.93% | Unkown | |
| HY-164756 | PKCTheta-IN-2 | Inhibitor | 99.49% | Unkown |
| HY-149056 | GNE-6893 | Inhibitor | 99.94% | Unkown |
| HY-169853 | M351-0056 | 99.48% | Unkown | |
| HY-100849 | JAK 3i | Inhibitor | 99.81% | Unkown |
| HY-150051 | IL-2-IN-1 | Inhibitor | 99.95% | Unkown |
| HY-21293 | SU5201 | Inhibitor | 99.45% | Unkown |
| HY-175547 | PROTAC HPK1 Degrader-5 | / | Unkown | |
| HY-112778 | NFAT Transcription Factor Regulator-1 | Inhibitor | 99.37% | Unkown |
| HY-113618A | RO2959 hydrochloride | Inhibitor | 99.12% | Unkown |
| HY-121638 | CU-3 | / | Unkown | |
| HY-135078 | 2,5-Deoxyfructosazine | Inhibitor | 98.05% | Unkown |
| HY-155978 | RDN2150 | Inhibitor | / | Unkown |
| HY-161389 | SP-alkyne | Inhibitor | / | Unkown |
| HY-163168 | aTAG 4531 | Degrader | 99.1% | Unkown |
| HY-A0003S | Lenalidomide-d5 | Inducer | 99.32% | Unkown |
| HY-P3143A | BMSpep-57 hydrochloride | Inhibitor | 99.69% | Unkown |
| HY-RS06749 | IL2RB Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06750 | IL2RG Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W048444 | Diaminobiotin | 99.9% | Unkown | |
| HY-Z8754 | Tacrolimus 8-epimer | 96.64% | Unkown | |
| HY-13756S2 | Tacrolimus-d3 | / | Unkown | |
| HY-149917 | PROTAC ITK degrader 1 | Degrader | / | Unkown |
| HY-168282 | DD205-291 | Degrader | / | Unkown |
| HY-P1453 | CMD178 | Inhibitor | / | Unkown |
| HY-103390 | Ro26-4550 TFA | Antagonist | / | Unkown |
| HY-10612A | Iso-AS601245 TFA | Inhibitor | / | Unkown |
| HY-108161 | LF 1695 | Activator | / | Unkown |
| HY-110113 | CTA056 | Inhibitor | / | Unkown |
| HY-112335 | Lck Inhibitor III | Inhibitor | / | Unkown |
| HY-112448 | Lck-IN-6 | Inhibitor | / | Unkown |
| HY-113494R | Sitostanol (Standard) | Activator | / | Unkown |
| HY-114980 | BMS-279700 | Inhibitor | / | Unkown |
| HY-115464 | NC1153 | / | Unkown | |
| HY-115756 | 4-Maleimidosalicylic acid | / | Unkown | |
| HY-117843 | Ppc-1 | / | Unkown | |
| HY-120457 | WYE-151650 | Inhibitor | / | Unkown |
| HY-121743 | Ro26-4550 | Antagonist | / | Unkown |
| HY-121874 | EP009 | Inhibitor | / | Unkown |
| HY-123221 | RS-0481 | Activator | / | Unkown |
| HY-124665 | LMP-420 | / | Unkown | |
| HY-126370 | Geranylgeranyl pyrophosphate | / | Unkown | |
| HY-132304A | (1S,4R)-CC-90005 | Control | 99.95% | Unkown |
| HY-141864 | ITK/TRKA-IN-1 | Inhibitor | / | Unkown |
| HY-145675A | (R)-TCB2 | / | Unkown | |
| HY-147504 | Anticancer agent 63 | / | Unkown | |
| HY-149201 | VISTA-IN-1 | / | Unkown | |
| HY-149206 | HPK1-IN-33 | Inhibitor | / | Unkown |
| HY-149232 | HPK1-IN-35 | Inhibitor | / | Unkown |
| HY-149916 | A2AR-antagonist-1 | Antagonist | 96.68% | Unkown |
| HY-153952 | Immuno modulator-1 | Inhibitor | / | Unkown |
| HY-156149 | CYP51/PD-L1-IN-1 | Inhibitor | / | Unkown |
| HY-156150 | CYP51/PD-L1-IN-2 | Inhibitor | / | Unkown |
| HY-156151 | CYP51/PD-L1-IN-3 | Inhibitor | / | Unkown |
| HY-157569 | PD1-PDL1-IN 2 | / | Unkown | |
| HY-157838 | HMC-B17 | Inhibitor | / | Unkown |
| HY-159892 | PD-1/PD-L1-IN-54 | / | Unkown | |
| HY-159902 | KRN7000 analog 3 | Activator | / | Unkown |
| HY-161390 | SPC-alkyne | Inhibitor | / | Unkown |
| HY-163194 | Cbl-b-IN-16 | Inhibitor | / | Unkown |
| HY-163496 | HPK1-IN-45 | Inhibitor | / | Unkown |
| HY-16362 | Omtriptolide sodium | / | Unkown | |
| HY-163747 | VEGFR-2-IN-47 | Inhibitor | / | Unkown |
| HY-163849 | Mizoribine prodrug-1 | Inhibitor | / | Unkown |
| HY-163850 | Mizoribine prodrug-2 trifluoroacetate | Inhibitor | / | Unkown |
| HY-169317 | DGKζ-IN-6 | Inhibitor | / | Unkown |
| HY-169318 | DGKζ-IN-7 | Inhibitor | / | Unkown |
| HY-172107 | HPK1-IN-56 | / | Unkown | |
| HY-172594 | HPK1-IN-57 | / | Unkown | |
| HY-172875 | HPK1-IN-58 | / | Unkown | |
| HY-173311 | Cbl-b-IN-28 | / | Unkown | |
| HY-173601 | JAK3-IN-17 | Inhibitor | / | Unkown |
| HY-174132 | CW8001 | Inhibitor | / | Unkown |
| HY-175195 | Adenosine receptor antagonist 6 | / | Unkown | |
| HY-175780 | CD28-IN-1 | Inhibitor | / | Unkown |
| HY-178062 | DGKα-IN-10 | / | Unkown | |
| HY-179111 | HPK1-IN-64 | Inhibitor | / | Unkown |
| HY-179338 | HPK1-IN-65 | / | Unkown | |
| HY-179575 | Cbl-b-IN-29 | / | Unkown | |
| HY-179617 | Cbl-b-IN-30 | Inhibitor | / | Unkown |
| HY-179727 | PROTAC HPK1 Degrader-7 | Activator | / | Unkown |
| HY-180608 | TCR-IN-1 | Inhibitor | / | Unkown |
| HY-180609 | TCR-IN-2 | Inhibitor | / | Unkown |
| HY-181924 | HPK1-IN-68 | / | Unkown | |
| HY-182238 | HPK1-IN-69 | / | Unkown | |
| HY-182369 | VA06 | Inhibitor | / | Unkown |
| HY-182765 | VAV1 degrader-4 | / | Unkown | |
| HY-182795 | Colchicine derivative-1 | / | Unkown | |
| HY-182799 | IBA-12 | Degrader | / | Unkown |
| HY-182945 | IKZF2-degrader 5 | / | Unkown | |
| HY-183317 | IDO1-IN-34 | / | Unkown | |
| HY-183539 | INCB191358 | Inhibitor | / | Unkown |
| HY-183997 | Cbl-b-IN-33 | / | Unkown | |
| HY-184230 | PROTAC HPK1 Degrader-8 | / | Unkown | |
| HY-184275 | ITK-IN-7 | Inhibitor | / | Unkown |
| HY-184745 | HPK1-IN-71 | / | Unkown | |
| HY-19009B | Propagermanium | Inhibitor | / | Unkown |
| HY-A0003S2 | Lenalidomide-13C5,15N | Inducer | / | Unkown |
| HY-B0199AS | Mycophenolate Mofetil-d4 hydrochloride | Inhibitor | / | Unkown |
| HY-N12988 | Dihydrobonducellin | Inhibitor | / | Unkown |
| HY-N16431 | NFAT-133 | / | Unkown | |
| HY-N1726 | cis-Burchellin | Inhibitor | / | Unkown |
| HY-N19727 | Chamissonolide | Inhibitor | / | Unkown |
| HY-N19872 | Mukurozioside IIb | / | Unkown | |
| HY-N19873 | Mukurozioside IIa | / | Unkown | |
| HY-P10544 | Humanized anti-tac (HAT) binding peptide | Inhibitor | / | Unkown |
| HY-P10994 | Eps8 peptide 327 | / | Unkown | |
| HY-P10995 | TAT-327 | / | Unkown | |
| HY-P11298 | d-T101 peptide | Activator | / | Unkown |
| HY-P3083 | N-Myristoyl-Lys-Arg-Thr-Leu-Arg | Inhibitor | / | Unkown |
| HY-P3736 | Myelopeptide-2 | Inducer | / | Unkown |
| HY-P5870 | KTX-Sp2 | Inhibitor | / | Unkown |
| HY-RS06728 | IL2 Human Pre-designed siRNA Set A | / | Unkown | |
| HY-RS06729 | Il2 Mouse Pre-designed siRNA Set A | / | Unkown | |
| HY-RS06730 | Il2 Rat Pre-designed siRNA Set A | / | Unkown | |
| HY-RS06748 | IL2RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W761985 | Furathiocarb | / | Unkown | |
| HY-W777675 | 2,5-Deoxyfructosazine-13C4 | / | Unkown | |
| HY-Y0344H | Sodium chloride, United States Pharmacopeia (USP) Reference Standard | / | Unkown | |
| HY-101687 | Nosantine racemate | / | Unkown | |
| HY-119514 | BC12 | Inhibitor | / | Unkown |
| HY-123187 | AS2553627 | Inhibitor | / | Unkown |
| HY-123590 | BC12-4 | Inhibitor | / | Unkown |
| HY-132243 | NFAT Inhibitor-3 | Inhibitor | / | Unkown |
| HY-161335 | HPK1-IN-43 | / | Unkown | |
| HY-163902 | SP100030 analogue 1 | Inhibitor | / | Unkown |
| HY-170616 | JH-FK-08 | Inhibitor | / | Unkown |
| HY-171004 | KRN7000 analog 8 | / | Unkown | |
| HY-173077 | PD-L1/LpxC-IN-1 | Inhibitor | / | Unkown |
| HY-174611 | Human IL2RA mRNA | / | Unkown | |
| HY-174625 | Human IL2 mRNA | 92.6% | Unkown | |
| HY-177058 | DSP30 | Agonist | 95.27% | Unkown |
| HY-181507 | CD28-IN-3 | Inhibitor | / | Unkown |
| HY-181821 | MMV1581361 | Inhibitor | / | Unkown |
| HY-183924 | SYK-IN-14 | Inhibitor | / | Unkown |
| HY-A0003S3 | Lenalidomide-d4 | Inducer | / | Unkown |
| HY-B0757 | Vitamin E nicotinate | Inhibitor | / | Unkown |
| HY-N0594R | Deacetylasperulosidic Acid (Standard) | / | Unkown | |
| HY-N12783 | Digitoxigenin-3-O-β-D-quinovoside | Inhibitor | / | Unkown |
| HY-N15307 | Trigraecum | Inhibitor | / | Unkown |
| HY-RS16278 | Il2rb Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS17342 | Il2rb Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS18825 | Il2ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS20039 | Il2rg Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS25315 | Il2ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS26542 | Il2rg Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Inhibitory Antibodies
(30)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990864 | Anti-CD3 Antibody (OKT-3) | Inhibitor | 97.94% | Unkown |
| HY-P990281 | Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) | 99% | Unkown | |
| HY-P990219 | Anti-Mouse IL-2 Antibody (JES6-1A12) | Inhibitor | 99% | Unkown |
| HY-P99877 | Efavaleukin alfa | ≥99.0% | Unkown | |
| HY-P99943 | Erfonrilimab | 99.98% | Unkown | |
| HY-P990736 | Efercoleukin alfa | 99.9% | Unkown | |
| HY-P99680 | Keliximab | Inhibitor | 98.23% | Unkown |
| HY-P992030 | FB102 | 99.17% | Unkown | |
| HY-P990796 | Anti-Mouse IL-2 Antibody (S4B6-1) | Inhibitor | 96.97% | Unkown |
| HY-P991828 | Anti-Mouse IL-2 Antibody (JES6-5H4) | Inhibitor | 98.62% | Unkown |
| HY-P991208 | Flt-3L-Ig (hum/hum) | 98% | Unkown | |
| HY-P991119 | Balekafusp alfa | Inhibitor | 96.37% | Unkown |
| HY-P991999 | OM-RCA-01 | ≥99.0% | Unkown | |
| HY-P992074 | Zemlikafusp alfa | Ligand | / | Unkown |
| HY-P992109 | Eftezirleukin alfa | / | Unkown | |
| HY-P990808 | Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) | Inhibitor | 95% | Unkown |
| HY-P990292 | Anti-Mouse CD132 (common γ chain) Antibody (3E12) | Inhibitor | / | Unkown |
| HY-P990986 | Efdelikofusp alfa | / | Unkown | |
| HY-P991270 | MT204 | Inhibitor | / | Unkown |
| HY-P991696 | Lecomkafusp alfa | / | Unkown | |
| HY-P991749 | Anti-Rat CD25 Antibody (OX-39) | Inhibitor | / | Unkown |
| HY-P991762 | Anti-Rat CD4 Antibody (W3/25) | Inhibitor | / | Unkown |
| HY-P992029 | RTX-003 | / | Unkown | |
| HY-P992031 | Anti-IL-2R gamma Antibody | Inhibitor | / | Unkown |
| HY-P992161 | REGN-10597 | / | Unkown | |
| HY-P992162 | 23ME-00610 | / | Unkown | |
| HY-P992370 | HPN601 | Inhibitor | / | Unkown |
| HY-P992401 | M802 | / | Unkown | |
| HY-P990293 | Anti-Mouse CD122/IL-2Rβ Antibody (5H4) | Inhibitor | ≥95.0% | Unkown |
| HY-P990866 | Anti-CD25/IL-2Rα Antibody (7G7B6) | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service